244 results
8-K
EX-10.2
ADXS
Ayala Pharmaceuticals, Inc.
5 Mar 24
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
ADXS
Ayala Pharmaceuticals, Inc.
5 Mar 24
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
ADXS
Ayala Pharmaceuticals, Inc.
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:51am
8-K
EX-10.1
ngaxc6bty 8w
21 Sep 23
Entry into a Material Definitive Agreement
4:05pm
425
EX-10.1
8vvbrltu6xksifl770j
2 Dec 22
Business combination disclosure
4:51pm
8-K
EX-10.1
sajn8tu a8k
2 Dec 22
Entry into a Material Definitive Agreement
4:49pm
425
EX-10.1
e29y kqt0yiax
19 Oct 22
Business combination disclosure
4:32pm
425
EX-10.2
7g5pmbcngau kwncfxef
19 Oct 22
Business combination disclosure
4:32pm
8-K
EX-10.1
7jvqwloxf3a jmjp6
19 Oct 22
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
4:31pm
8-K
EX-10.2
kkrs5q19k
19 Oct 22
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
4:31pm
8-K
EX-10.2
6xkws
28 Jan 22
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement
5:29pm